Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Beijing Tsinghua Chang Gung Hospital

Status: Unknown

Conditions: Fatty Liver Disease

Treatments: Diagnostic Test: Fibrotouch

Study type: Observational

Funder types: Other

Identifiers

NCT05421572

CG-MAFLD-001

Details and patient eligibility

About

To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China

Full description

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease all over the world (1). In early 2020, a new definition of MAFLD has been proposed and is becoming increasingly widely accepted. The new diagnostic criteria are based on the histology or imaging of liver biopsies, or even blood biomarker tests indicative of the presence of fatty liver while satisfying any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction (2). The information on the prevalence of MAFLD is scarce. This study is designed to conduct MAFLD screening in adults with health check-ups at multiple health examination centers across China. The primary objective is to investigate the prevalence of MAFLD among adults in China.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Aged between 18 and 75, both sex;
• Able to sign informed consent.

Exclusion criteria

• Pregnant women and those who are implanted with pacemakers, stents or any other metal devices.

Trial design

2,000 participants in 1 patient group

Single Group Assignment

Description:

Adults with health check-ups at multiple health examination centers across China

Treatment:

Diagnostic Test: Fibrotouch